NEW YORK –The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Tesaro, Inc. (“Tesaro” or the “Company”) (NASDAQ:TSRO) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/TSRO-Info-Request-Form-1781. There is no cost or obligation to you.
On January 12, 2018, Tesaro announced it had updated the U.S. labeling of VARUBI® (rolapitant) injectable emulsion packages after reports that some patients receiving the treatment experienced “Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions.”
To learn more about the investigation of Tesaro contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/TSRO-Info-Request-Form-1781.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.